HUN

HUNTSMAN CORP

Basic Materials | Small Cap

$0.07

EPS Forecast

$1,624

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Huntsman’s Quiet Q2 2026: A Slim Loss, A Big Merger on the Horizon

For NYSE: HUN watchers, the quarter offered a curious mix: an almost-never-seen earnings surprise in the sense of a dramatic reversal, a tiny EPS headwind versus last year, and a strategic pivot that could redefine the company’s trajectory. This is the kind of release that invites questions about guidance, capital allocation, and what a merger of equals with Olin Corporation might mean for the chemical landscape going forward.

Executive snapshot

  • Ticker: HUN (NYSE).
  • Quarter: Second quarter 2026. Net loss attributable to Huntsman: $6 million.
  • EPS: Diluted loss per share of $0.03, versus a loss per share of $0.92 in the prior-year period.
  • Adjusted metrics: Adjusted net income attributable to Huntsman nil, and adjusted diluted EPS nil, versus prior-year adjustments of nil and $0.20 (adjusted).
  • Operational cash flow: Net cash used in operating activities from continuing operations $60 million in Q2 2026. Free cash flow was a use of cash of $90 million for Q2 2026, versus a source of cash of $55 million in the prior year period.
  • Capital development: Remaining at the level of a business in transition, with a notable shift toward stock-based strategic initiatives rather than simple cash deployment.
  • Strategic event: On June 16, 2026, Huntsman announced an all-stock merger of equals with Olin Corporation.

In short order, the numbers sketch a company that is narrowing its quarterly loss, but still burning cash in the near term, while leaning into a transformative, scale-building merger. Investors will be watching for how the EPS consensus and revenue forecast for the combined entity form over the next several quarters.

What Huntsman reported

The company pointed to a significant swing from a year-ago loss to a much smaller net loss in the reported quarter, with a muted impact on earnings per share that reflects the combination of improved operating performance and ongoing expenses or headwinds that keep EPS negative on a GAAP basis. The standout line is adjusted EBITDA, which reached about $120 million for the quarter, up from roughly $74 million a year earlier. This suggests that underlying earnings power is accruing, even as the cash flow statements tell a more cautious story.

On the liquidity front, Huntsman disclosed that net cash from operating activities from continuing operations was negative in the quarter, with free cash flow showing a use of cash. Those cash dynamics matter as the company positions itself for the merger deal announced in mid-June. The EPS result, especially on a GAAP basis, remains a function of mix, costs, and the integration path ahead, rather than a simple line-item beat or miss against a standing street estimate.

The Olin merger: implications and questions

Huntsman disclosed an all-stock merger of equals with Olin Corporation, signaling a strategic intent to accelerate scale, diversify portfolio breadth, and potentially improve margin resilience through shared technology and geographic reach. An all-stock structure shifts the value narrative: the deal’s success hinges on post-merger synergies and the market’s willingness to assign cross-company value to combined operating performance rather than to the individual entities’ current balance sheets.

For a revenue forecast and earnings outlook, investors will be looking to the leveraged benefits of combined procurement, cross-selling opportunities, and asset optimization. The absence of an upfront cash consideration in the merger can alleviate near-term liquidity pressures, but it also puts a spotlight on the timing and magnitude of integration-related costs and capability overlaps.

The risk matrix is non-trivial: antitrust scrutiny in a chemistry-and-polymer-heavy sector, potential exposure to commodity cycles, and the challenge of integrating two large, multi-product businesses with distinct customer bases. Still, the all-stock structure could preserve capital while signaling confidence in a longer-term earnings arc, should the combined company realize meaningful cost synergies and revenue accelerants.

What this could mean for Huntsman’s peers and the sector

If the Q2 results and the Olin deal withstand scrutiny, sector peers might reassess scale strategies, particularly those balancing specialty chemicals with broad commodity exposure. A successful integration could serve as a blueprint for how to pair chemical platforms with complementary end-markets—coatings, polymers, and performance materials—without overspending on immediate capex.

The narrative here also touches on a broader theme: corporations in capital-intensive, cyclical industries increasingly favor selective growth through mergers that lean on equity rather than cash. In practice, this can translate into more disciplined cash management, a clearer emphasis on EBITDA-quality upside, and a market that prices future synergies into the stock over time rather than in a single reporting period.

What to watch next

  • EPS trajectory post-merger: Investors will want to see how the GAAP and non-GAAP EPS lines evolve as the integration progresses and as the company communicates updated guidance.
  • Revenue trajectory and margin mix: Any shift in product mix, pricing discipline, or geographic exposure could influence the revenue forecast and EBITDA margin mix of the combined entity.
  • Capital allocation posture: The shift to an all-stock deal implies a different approach to capital structure and debt capacity. Watch for reporting on synergy payback timelines and any incremental funding needs for integration.
  • Sector peer effects: If the merger traverses antitrust hurdles smoothly and delivers tangible synergies, other chemical manufacturers might pursue parallel consolidations or strategic partnerships to survive a volatile commodity cycle.

Bottom line

Huntsman’s Q2 2026 results read as a transitional report: a narrowed GAAP loss, an improving though still cash-burning near term, and a strategic pivot toward a larger, arguably more durable platform via the merger with Olin. For investors tracking EPS and the EPS consensus around the post-merger entity, the near-term read is cautious but not lifeless: the adjusted EBITDA movement hints at real earnings power if the integration path pays off.

In the broader chemical universe, this kind of all-stock merger signals a preference for scale and diversification to weather cyclical ups and downs, while preserving flexibility in the near term. The market reaction will hinge on how convincingly Huntsman and Olin articulate the path to synergy, the pace of integration, and the degree to which a combined portfolio can withstand OEM cycles, raw material volatility, and competitive pressure.

For readers tracking ticker symbols, earnings metrics, and the evolving dialogue around mergers in the chemical sector, this episode offers a case study in balancing near-term disappointment with long-run strategic bets. As always, the numbers will talk, but the corporate narrative—what investors can unlock from the combined scale—will shout.